Spero Therapeutics
Stock Forecast, Prediction & Price Target
Spero Therapeutics Financial Estimates
Spero Therapeutics Revenue Estimates
Spero Therapeutics EBITDA Estimates
Spero Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.25M N/A | $48.57M 166.09% | $96.73M 99.12% | Avg: $34.43M Low: $29.27M High: $37.75M avg. -64.40% | Avg: $56.25M Low: $47.82M High: $61.67M avg. 63.35% | Avg: $80.65M Low: $68.56M High: $88.43M avg. 43.37% | Avg: $131.6M Low: $111.88M High: $144.30M avg. 63.17% |
Net Income
% change YoY
| $-91.30M N/A | $-48.02M 47.39% | $22.80M 147.48% | Avg: $-72.9M Low: $-90.08M High: $-46.10M avg. -419.65% | Avg: $-41.1M Low: $-63.58M High: $-4.76M avg. 43.62% | Avg: $-11.12M Low: $-12.52M High: $-8.95M avg. 72.92% | Avg: $29.14M Low: $23.46M High: $32.80M avg. 361.90% |
EBITDA
% change YoY
| $-87.37M N/A | $-18.93M 78.32% | $25.77M 236.08% | Avg: $-21.91M Low: $-24.02M High: $-18.62M avg. -185.02% | Avg: $-35.79M Low: $-39.25M High: $-30.43M avg. -63.35% | Avg: $-51.32M Low: $-56.27M High: $-43.63M avg. -43.37% | Avg: $-83.74M Low: $-91.83M High: $-71.19M avg. -63.17% |
EPS
% change YoY
| -$2.96 N/A | -$1.28 56.75% | $0.43 133.59% | Avg: -$1.2 Low: -$1.7 High: -$0.87 avg. -379.06% | Avg: -$0.65 Low: -$1.2 High: -$0.09 avg. 46.25% | Avg: -$0.21 Low: -$0.24 High: -$0.17 avg. 67.44% | Avg: $0.55 Low: $0.44 High: $0.62 avg. 361.90% |
Operating Expenses
% change YoY
| $106.22M N/A | $79.14M -25.49% | $75.25M -4.91% | Avg: $61.18M Low: $52.01M High: $67.09M avg. -18.69% | Avg: $99.95M Low: $84.97M High: $109.59M avg. 63.35% | Avg: $143.30M Low: $121.83M High: $157.13M avg. 43.37% | Avg: $233.84M Low: $198.80M High: $256.41M avg. 63.17% |
FAQ
What is Spero Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.69% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -90.08M, average is -72.9M and high is -46.10M.
What is Spero Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 26.37% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $29.27M, average is $34.43M and high is $37.75M.
What is Spero Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 24.13% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.7, average is -$1.2 and high is $-0.87.